US Patent

US8247411 — Sulfonyl amide derivatives for the treatment of abnormal cell growth

Composition of Matter · Assigned to Pfizer Inc · Expires 2028-04-17 · 2y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects novel sulfonyl amide derivatives for treating abnormal cell growth, such as cancer, in mammals.

USPTO Abstract

The present invention relates to a compound of the formula I wherein R 1 to R 6 , A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Drugs covered by this patent

Patent Metadata

Patent number
US8247411
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-04-17
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.